SEARCH
検索詳細
松尾 和浩 (マツオ カズヒロ)
| 総合イノベーション創発機構ワクチン研究開発拠点 | 特任教授 |
研究者基本情報
■ 学位■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究キーワード研究分野■ 担当教育組織
- 博士課程, 国際感染症学院
研究活動情報
■ 論文- Mycobacterial α-glucans hijack dectin-1 to facilitate intracellular bacterial survival
Shota Torigoe; Sumayah Salie; Roanne Keeton; Beren Aylan; Ben J. Appelmelk; David L. Williams; Douglas W. Lowman; Toshihiko Sugiki; Sohkichi Matsumoto; Akira Kawano; Satoru Mizuno; Kazuhiro Matsuo; Jonas N. Søndergaard; James B. Wing; Maxine A. Höft; Romey Shoesmith; Mthawelanga Ndengane; Anna K. Coussens; Janet A. Willment; Maximiliano G. Gutierrez; Jennifer Claire Hoving; Sho Yamasaki; Gordon D. Brown
Science Immunology, 11, 115, American Association for the Advancement of Science (AAAS), 2026年01月09日
研究論文(学術雑誌), Mycobacteria have a cell envelope that can act as a shield against host defense. This study shows that mycobacteria survive in host macrophages by targeting the innate host receptor dectin-1 through a noncanonical ligand. Compared with wild-type (WT) mice, dectin-1–deficient mice were more resistant to infection to mycobacteria. Dectin-1–deficient mice presented with substantially reduced bacterial burdens, inflammatory cytokines, and infiltrating myeloid cells, such as neutrophils and macrophages. Intracellular survival of these bacteria was reduced in macrophages derived from dectin-1–deficient mice compared with those from WT mice. Cellular characterization of mycobacteria-infected macrophages indicated that the presence of dectin-1 altered phagosomal maturation and association with markers of autophagy. Activity-based purification and nuclear magnetic resonance spectrometry identified branched α-glucan as the dectin-1 mycobacterial ligand. This branched glucan was essential for activating dectin-1. These results show that mycobacterial α-glucan targets dectin-1 to facilitate intracellular bacterial survival. - Efficient recombinant protein secretion in Mycobacterium smegmatis: A valuable platform for protein production involved in biomedical development targeting mycobacterial diseases
Hiroto Takeuchi; Satoru Mizuno; Kazuhiro Matsuo
Journal of Biotechnology, Elsevier BV, 2025年11月
研究論文(学術雑誌) - Development of a Novel Mucosal Vaccine Vector Derived From Human Parainfluenza Virus Type 2 and Its Efficacy as a SARS-CoV-2 Vaccine by Intratracheal Administration Using Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2.
Akira Kawano; Masamitsu N Asaka; Mitsuo Kawano; Hidehisa Sekijima; Kae Sakai-Sugino; Hiroshi Komada; Natsuko Yamakawa; Shigeo Horibata; Kazuhiro Matsuo; Myles O'Brien; Tetsuya Nosaka; Yasuhiro Yasutomi
Genes to cells : devoted to molecular & cellular mechanisms, 30, 6, e70058, 2025年11月, [国際誌]
英語, 研究論文(学術雑誌), We created a novel replication-incompetent vector derived from the human parainfluenza virus type 2 (hPIV2). The vector lacks the hemagglutinin-neuraminidase (HN) gene (hPIV2/∆HN) that is essential for virus attachment and release. We also generated the stable packaging cell line expressing hPIV2 HN protein derived from Vero cells (Vero-HN). As SARS-CoV-2 vaccines, we created hPIV2/∆HN-based SARS-CoV-2 vaccines expressing the receptor binding domain of the spike protein (S-RBD) of SARS-CoV-2, and S-RBD with trimer formation domain (S-RBD-FD) with or without antigen 85B (Ag85B) having strong Th1-type cytokine inducing activity. Intratracheal administration of S-RBD-FD/hPIV2/∆HN and S-RBD-FD/Ag85B/hPIV2/∆HN induced the S-RBD-specific neutralizing antibodies in sera of transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2/TG), and also the sera neutralized the pseudo-typed lentivirus expressing the SARS-CoV-2 S protein. In particular, in an S-RBD-FD/Ag85B/hPIV2/∆HN-administered group, high levels of neutralizing antibodies were induced also in the bronchoalveolar lavage fluid (BALF) in the hACE2/TG mice. Further, hACE2/TG mice vaccinated with S-RBD-FD/hPIV2/∆HN or S-RBD-FD/Ag85B/hPIV2/∆HN did not exhibit weight loss and showed a high survival rate after authentic SARS-CoV-2 challenge. These results suggested that S-RBD-FD/Ag85B/hPIV2/∆HN is a vaccine candidate against SARS-CoV-2. Finally, hPIV2/∆HN or Ag85B/hPIV2/∆HN vector will be potentially applicable to vaccine development and/or human gene therapy for respiratory tract diseases. - Retinoic acid receptor-related orphan receptor α regulates bystander activation of memory CD8+ T cells
Zimeng Cai; Mina Kozai; Hironobu Mita; Hiroto Takeuchi; Satoru Mizuno; Kazuhiro Matsuo; Kensuke Takada
Frontiers in Immunology, 16, 2025年08月, [査読有り]
英語 - Roles of tumor necrosis factor-like ligand 1A in γδT-cell activation and psoriasis pathogenesis
Shangyi Wang; Mina Kozai; Masaya Hiraishi; Md. Zahir Uddin Rubel; Osamu Ichii; Mutsumi Inaba; Kazuhiro Matsuo; Kensuke Takada
Frontiers in Immunology, 15, 1340467, Frontiers Media SA, 2024年01月29日, [査読有り]
英語, 研究論文(学術雑誌), Background
Interleukin (IL)-17-producing γδT (γδT17) cells mediate inflammatory responses in barrier tissues. Dysregulated γδT17 cell activation can lead to the overproduction of IL-17 and IL-22 and the development of inflammatory diseases, including psoriasis. IL-23 and IL-1β are known to synergistically activate γδT17 cells, but the regulatory mechanisms of γδT17 cells have not been fully elucidated. This study aimed to reveal the contribution of the inflammatory cytokine tumor necrosis factor-like ligand 1A (TL1A) to γδT17 cell activation and psoriasis development.
Methods
Anti-TL1A antibody was injected into an imiquimod (IMQ)-induced murine psoriasis model. TL1A receptor expression was analyzed in splenic and dermal γδT cells. γδT cells were tested for cytokine production in vitro and in vivo under stimulation with IL-23, IL-1β, and TL1A. TL1A was applied to a psoriasis model induced by intradermal IL-23 injection. Mice deficient in γδT cells were intradermally injected with IL-23 plus TL1A to verify the contribution of TL1A-dependent γδT-cell activation to psoriasis development.
Results
Neutralization of TL1A attenuated γδT17 cell activation in IMQ-treated skin. TL1A induced cytokine production by splenic γδT17 cells in synergy with IL-23. Dermal γδT17 cells constitutively expressed a TL1A receptor at high levels and vigorously produced IL-22 upon intradermal IL-23 and TL1A injection but not IL-23 alone. TL1A exacerbated the dermal symptoms induced by IL-23 injection in wild-type but not in γδT cell–deficient mice.
Conclusion
These findings suggest a novel regulatory mechanism of γδT cells through TL1A and its involvement in psoriasis pathogenesis as a possible therapeutic target. - The Induction of Antigen 85B-Specific CD8+ T Cells by Recombinant BCG Protects against Mycobacterial Infection in Mice.
Shihoko Komine-Aizawa; Satoru Mizuno; Akira Kawano; Satoshi Hayakawa; Kazuhiro Matsuo; Mitsuo Honda
International journal of molecular sciences, 24, 2, 2023年01月04日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Mycobacterium tuberculosis (Mtb) infection remains a major health problem worldwide. Although the Bacillus Calmette-Guérin (BCG) vaccine is the most widely used vaccination for preventing tuberculosis (TB), its efficacy is limited. We previously developed a new recombinant BCG (rBCG)-based vaccine encoding the Ag85B protein of M. kansasii (Mkan85B), termed rBCG-Mkan85B, and its administration is followed by boosting with plasmid DNA expressing the Ag85B gene (DNA-Mkan85B). Previously, we identified MHC-I (H2-Kd)-restricted epitopes that highly cross-react with those of Mtb in BALB/c (H2d) and CB6F1 (H2b/d) mice. We also reported that the rBCG-Mkan85B/DNA-Mkan85B prime-boost vaccination protocol protected CB6F1 mice against M. kansasii infection. In this study, to investigate the protective effect of our novel rBCG against Mtb infection, CB6F1 mice were either left unimmunized or immunized with the BCG, rBCG-Mkan85B, or rBCG-Mkan85B/DNA-Mkan85B vaccine for 10 weeks prior to inhalation exposure to the virulent Mtb Erdman strain for another 6 weeks. Compared with the BCG and rBCG-Mkan85B vaccinations, the rBCG-Mkan85B/DNA-Mkan85B prime-boost vaccination protocol significantly reduced the numbers of pulmonary colony-forming units (CFUs). Moreover, the rBCG-Mkan85B/DNA-Mkan85B prime-boost vaccination induced antigen-specific polyfunctional CD4+ and CD8+ T cells. These results suggest that CD8+ T-cell immunity to immunodominant epitopes of Mtb is enhanced by rBCG vector-based immunization. Thus, rBCG vector-based vaccinations may overcome the limited ability of the current BCG vaccine to elicit TB immunity. - Culture filtrate proteins from BCG act as adjuvants for cytotoxic T lymphocyte induction
Satoru Mizuno; Yasushi Chuma; Yukihiro Shibuya; Shigeo Horibata; Tomoe Baba; Emi Yokokawa; Kazuhiro Matsuo
Frontiers in Immunology, 14, 1271228, 2023年, [査読有り], [責任著者]
英語, 研究論文(学術雑誌) - Mycobacterial mycolic acids trigger inhibitory receptor Clec12A to suppress host immune responses.
Naoya Nishimura; Noriyuki Tomiyasu; Shota Torigoe; Satoru Mizuno; Hanako Fukano; Eri Ishikawa; Harutaka Katano; Yoshihiko Hoshino; Kazuhiro Matsuo; Masatomo Takahashi; Yoshihiro Izumi; Takeshi Bamba; Koichi Akashi; Sho Yamasaki
Tuberculosis (Edinburgh, Scotland), 138, 102294, 102294, 2023年01月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Mycobacteria often cause chronic infection. To establish persistence in the host, mycobacteria need to evade host immune responses. However, the molecular mechanisms underlying the evasion strategy are not fully understood. Here, we demonstrate that mycobacterial cell wall lipids trigger an inhibitory receptor to suppress host immune responses. Mycolic acids are major cell wall components and are essential for survival of mycobacteria. By screening inhibitory receptors that react with mycobacterial lipids, we found that mycolic acids from various mycobacterial species bind to mouse Clec12A, and more potently to human Clec12A. Clec12A is a conserved inhibitory C-type lectin receptor containing immunoreceptor tyrosine-based inhibitory motif (ITIM). Innate immune responses, such as MCP-1 production, and PPD-specific recall T cell responses were augmented in Clec12A-deficient mice after infection. In contrast, human Clec12A transgenic mice were susceptible to infection with M. tuberculosis. These results suggest that mycobacteria dampen host immune responses by hijacking an inhibitory host receptor through their specific and essential lipids, mycolic acids. The blockade of this interaction might provide a therapeutic option for the treatment or prevention of mycobacterial infection. - Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against Mycobacterium kansasii.
Shihoko Komine-Aizawa; Satoru Mizuno; Kazuhiro Matsuo; Takahiro Namiki; Satoshi Hayakawa; Mitsuo Honda
Vaccines, 9, 11, 2021年11月01日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), The incidence of infections with nontuberculous mycobacteria (NTM) has been increasing worldwide. The emergence of multidrug-resistant NTM is a serious clinical concern, and a vaccine for NTM has not yet been developed. We previously developed a new recombinant Bacillus Calmette-Guérin (rBCG) vaccine encoding the antigen 85B (Ag85B) protein of Mycobacterium kansasii-termed rBCG-Mkan85B-which was used together with a booster immunization with plasmid DNA expressing the same M. kansasii Ag85B gene (DNA-Mkan85B). We reported that rBCG-Mkan85B/DNA-Mkan85B prime-boost immunization elicited various NTM strain-specific CD4+ and CD8+ T cells and induced Mycobacterium tuberculosis-specific immunity. In this study, to investigate the protective effect against M. kansasii infection, we challenged mice vaccinated with a rBCG-Mkan85B or rBCG-Mkan85B/DNA-Mkan85B prime-boost strategy with virulent M. kansasii. Although BCG and rBCG-Mkan85B immunization each suppressed the growth of M. kansasii in the mouse lungs, the rBCG-Mkan85B/DNA-Mkan85B prime-boost vaccination reduced the bacterial burden more significantly. Moreover, the rBCG-Mkan85B/DNA-Mkan85B prime-boost vaccination induced antigen-specific CD4+ and CD8+ T cells. Our data suggest that rBCG-Mkan85B/DNA-Mkan85B prime-boost vaccination effectively enhances antigen-specific T cells. Our novel rBCG could be a potential alternative to clinical BCG for preventing various NTM infections. - Long-term protective immunity induced by an adjuvant-containing live-attenuated AIDS virus.
Tomotaka Okamura; Yuya Shimizu; Masamitsu N Asaka; Tomohiro Kanuma; Yusuke Tsujimura; Takuya Yamamoto; Kazuhiro Matsuo; Yasuhiro Yasutomi
NPJ vaccines, 6, 1, 124, 124, 2021年10月22日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), The use of an adjuvant in vaccination is thought to be effective for enhancing immune responses to various pathogens. We genetically constructed a live attenuated simian human immunodeficiency virus (SHIV) to express the adjuvant molecule Ag85B (SHIV-Ag85B). SHIV-Ag85B could not be detected 4 weeks after injection in cynomolgus macaques, and strong SHIV-specific T cell responses were induced in these macaques. When the macaques in which SHIV-Ag85B had become undetectable were challenged with pathogenic SHIV89.6P at 37 weeks after SHIV-Ag85B had become undetectable, SHIV89.6P was not detected after the challenge. Eradication of SHIV89.6P was confirmed by adoptive transfer experiments and CD8-depletion studies. The SHIV-Ag85B-inoculated macaques showed enhancement of Gag-specific monofunctional and polyfunctional CD8+ T cells in the acute phase of the pathogenic SHIV challenge. The results suggest that SHIV-Ag85B elicited strong sterile immune responses against pathogenic SHIV and that it may lead to the development of a vaccine for AIDS virus infection. - Mycobacterium bovis BCG-mediated suppression of Th17 response in mouse experimental autoimmune encephalomyelitis.
Goro Matsuzaki; Naoko Teruya; Hideyasu Kiyohara Kohama; Keiko Arai; Yukihiro Shibuya; Yasushi Chuma; Kazuhiro Matsuo
Immunopharmacology and immunotoxicology, 43, 2, 203, 211, 2021年04月, [査読有り], [最終著者], [国際誌]
英語, 研究論文(学術雑誌), INTRODUCTION: Multiple sclerosis (MS) is an autoimmune disease mediated by a pro-inflammatory immune response. Experimental autoimmune encephalomyelitis (EAE) induced by immunization of mice with a myelin oligodendrocyte glycoprotein (MOG) peptide emulsified in killed Mycobacterium tuberculosis-containing complete Freund's adjuvant (CFA-EAE) is used as a model of MS. Mycobacterium bovis BCG has been reported to ameliorate clinical symptoms of CFA-EAE, although the precise mechanism has not yet been documented. Since CFA-EAE uses adjuvant with mycobacterial antigens, mycobacterial antigen-specific T cells induced by CFA may cross-react with BCG and modulate EAE. METHODS: To exclude the influence of cross-reactivity, a modified murine EAE model (cell wall skeleton (CWS)-EAE) that does not induce mycobacterial antigen-specific T cells was established and used to reevaluate the therapeutic effects of BCG on EAE. RESULTS: Inoculation with BCG 6 d after CWS-EAE induction successfully ameliorated EAE symptoms, suggesting that the therapeutic effects of BCG are independent of the mycobacterial antigen-specific T cells induced by the CFA-EAE protocol. BCG inoculation into the CWS-EAE mice resulted in reduced levels of MOG-specific Th17 in the central nervous system (CNS) with reduced demyelinated lesions of the spinal cord. In the draining lymph nodes of the MOG-immunized sites, BCG inoculation resulted in an increase in MOG-specific Th17 and Th1 cells at an early stage of immune response. CONCLUSION: The results suggest that BCG inoculation suppresses the Th17 response in the CNS of EAE mice via a mechanism that may involve the suppression of egress of encephalitogenic T cells from lymphoid organs. - A New Mouse Model of Chronic Myocarditis Induced by Recombinant Bacille Calmette-Guèrin Expressing a T-Cell Epitope of Cardiac Myosin Heavy Chain-α.
Kazuko Tajiri; Kyoko Imanaka-Yoshida; Yusuke Tsujimura; Kazuhiro Matsuo; Michiaki Hiroe; Kazutaka Aonuma; Masaki Ieda; Yasuhiro Yasutomi
International journal of molecular sciences, 22, 2, 2021年01月14日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Dilated cardiomyopathy (DCM) is a potentially lethal disorder characterized by progressive impairment of cardiac function. Chronic myocarditis has long been hypothesized to be one of the causes of DCM. However, owing to the lack of suitable animal models of chronic myocarditis, its pathophysiology remains unclear. Here, we report a novel mouse model of chronic myocarditis induced by recombinant bacille Calmette-Guérin (rBCG) expressing a CD4+ T-cell epitope of cardiac myosin heavy chain-α (rBCG-MyHCα). Mice immunized with rBCG-MyHCα developed chronic myocarditis, and echocardiography revealed dilation and impaired contraction of ventricles, similar to those observed in human DCM. In the heart, CD62L-CD4+ T cells were increased and produced significant amounts of IFN-γ and IL-17 in response to cardiac myosin. Adoptive transfer of CD62L-CD4+ T cells induced myocarditis in the recipient mice, which indicated that CD62L-CD4+ T cells were the effector cells in this model. rBCG-MyHCα-infected dendritic cells produced proinflammatory cytokines and induced MyHCα-specific T-cell proliferation and Th1 and Th17 polarization. This novel chronic myocarditis mouse model may allow the identification of the central pathophysiological and immunological processes involved in the progression to DCM. - Vaccination with Intradermal Bacillus Calmette-Guérin Provides Robust Protection against Extrapulmonary Tuberculosis but Not Pulmonary Infection in Cynomolgus Macaques.
Yusuke Tsujimura; Yumiko Shiogama; Shogo Soma; Tomotaka Okamura; Junichiro Takano; Emiko Urano; Yoshiko Murakata; Akira Kawano; Natsuko Yamakawa; Masamitsu N Asaka; Kazuhiro Matsuo; Yasuhiro Yasutomi
Journal of immunology (Baltimore, Md. : 1950), 205, 11, 3023, 3036, 2020年12月01日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Recently, the efficacy of Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination is being reassessed in accordance with the achievements of clinical tuberculosis (TB) vaccine research. However, the mechanisms ultimately determining the success or failure of BCG vaccination to prevent pulmonary TB remain poorly understood. In this study, we analyzed the protective effects of intradermal BCG vaccination by using specific pathogen-free cynomolgus macaques of Asian origin that were intradermally vaccinated with BCG (Tokyo strain) followed by Mycobacterium tuberculosis (Erdman strain) infection. Intradermal BCG administration generated TB Ag-specific multifunctional CD4 T cell responses in peripheral blood and bronchoalveolar lavage and almost completely protected against the development of TB pathogenesis with aggravation of clinical parameters and high levels of bacterial burdens in extrapulmonary organs. However, interestingly, there were no differences in bacterial quantitation and pathology of extensive granulomas in the lungs between BCG-vaccinated monkeys and control animals. These results indicated that the changes in clinical parameters, immunological responses, and quantitative gross pathology that are used routinely to determine the efficacy of TB vaccines in nonhuman primate models might not correlate with the bacterial burden and histopathological score in the lung as measured in this study. - CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts
Seiichi Kato; Hisatoshi Shida; Tomotaka Okamura; Xianfeng Zhang; Tomoyuki Miura; Tetsu Mukai; Makoto Inoue; Tsugumine Shu; Taeko K. Naruse; Akinori Kimura; Yasuhiro Yasutomi; Kazuhiro Matsuo
Journal of Virology, 95, 4, e01718-20, American Society for Microbiology, 2020年10月21日, [査読有り], [責任著者]
研究論文(学術雑誌), Toward development of a dual vaccine for human immunodeficiency virus (HIV)-1 and tuberculosis infections, we developed a urease-deficient bacillus Calmette-Guérin (BCG) strain Tokyo172 (BCGΔurease) to enhance its immunogenicity. BCGΔurease expressing simian immunodeficiency virus (SIV) Gag induced BCG antigen-specific CD4+ and CD8+ T cells more efficiently, and more Gag-specific CD8+ T cells. We evaluated its protective efficacy against SIV infection in cynomolgus monkeys of Asian origin, shown to be as susceptible to infection with SIVmac251 as Indian rhesus macaques. Priming with recombinant BCG (rBCG) expressing SIV genes was followed by a boost with SIV gene-expressing LC16m8Δ vaccinia virus and a second boost with SIV Env-expressing Sendai virus (SeV). Eight weeks after the second boost, monkeys were repeatedly challenged with a low dose of SIVmac251 intrarectally. Two animals out of 6 vaccinees were protected whereas all 7 control animals were infected without any early viral controls. In one vaccinated animal, which had the most potent CD8+ T cells in anin vitro suppressive activity (ISA) assay of SIVmac239 replication, plasma viremia was undetectable throughout the follow-up period. Protection was confirmed by lack of anamnestic antibody responses and detectable cell-associated provirus in various organs. Another monkey with a high ISA acquired a small amount of SIV, but it later became suppressed below the detection limit. Moreover, the ISA score correlated with SIV acquisition. On the other hand, any parameter relating anti-Env antibody was not correlated with the protection.IMPORTANCE Because both AIDS and tuberculosis are serious health threats in middle/low income countries, development of a dual vaccine against them would be highly beneficial. To approach the goal, here we first assessed a urease-deficient bacillus Calmette-Guérin (BCG) for improvement of immunogenicity against bothM. tuberculosis and SIV. Secondly, we demonstrated usefulness of Asian origin cynomolgus monkeys for a preclinical AIDS vaccine development by direct comparison with Indian rhesus macaques as the only validated hosts that identically mirror the outcomes of clinical trials, since the availability of Indian rhesus macaques is limited in countries other than the United States. Finally, we report the protective effect of a vaccination regimen comprising BCG, highly attenuated vaccinia virus LC16m8Δ strain, and non-transmissible Sendai virus as safe vectors expressing SIV genes using repeated mucosal challenge with highly pathogenic SIVmac251. Identification of CD8+ T cells as a protective immunity suggests future direction of AIDS vaccine development. - MHC-restricted Ag85B-specific CD8+ T cells are enhanced by recombinant BCG prime and DNA boost immunization in mice.
Shihoko Komine-Aizawa; Jiansheng Jiang; Satoru Mizuno; Satoshi Hayakawa; Kazuhiro Matsuo; Lisa F Boyd; David H Margulies; Mitsuo Honda
European journal of immunology, 49, 9, 1399, 1414, 2019年09月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Despite efforts to develop effective treatments and vaccines, Mycobacterium tuberculosis (Mtb), particularly pulmonary Mtb, continues to provide major health challenges worldwide. To improve immunization against the persistent health challenge of Mtb infection, we have studied the CD8+ T cell response to Bacillus Calmette-Guérin (BCG) and recombinant BCG (rBCG) in mice. Here, we generated CD8+ T cells with an rBCG-based vaccine encoding the Ag85B protein of M. kansasii, termed rBCG-Mkan85B, followed by boosting with plasmid DNA expressing the Ag85B gene (DNA-Mkan85B). We identified two MHC-I (H2-Kd )-restricted epitopes that induce cross-reactive responses to Mtb and other related mycobacteria in both BALB/c (H2d ) and CB6F1 (H2b/d ) mice. The H2-Kd -restricted peptide epitopes elicited polyfunctional CD8+ T cell responses that were also highly cross-reactive with those of other proteins of the Ag85 complex. Tetramer staining indicated that the two H2-Kd -restricted epitopes elicit distinct CD8+ T cell populations, a result explained by the X-ray structure of the two peptide/H2-Kd complexes. These results suggest that rBCG-Mkan85B vector-based immunization and DNA-Mkan85B boost may enhance CD8+ T cell response to Mtb, and might help to overcome the limited effectiveness of the current BCG in eliciting tuberculosis immunity. - SOCS1 Antagonist-Expressing Recombinant Bacillus Calmette-Guérin Enhances Antituberculosis Protection in a Mouse Model.
Mizuno S; Soma S; Inada H; Kanuma T; Matsuo K; Yasutomi Y
Journal of immunology (Baltimore, Md. : 1950), 203, 1, 188, 197, 2019年05月, [査読有り] - Primary Role of Suppressor of Cytokine Signaling 1 in Mycobacterium bovis BCG Infection.
Shogo Soma; Satoru Kawai; Hiroyasu Inada; Kenta Watanabe; Satoru Mizuno; Seiichi Kato; Kazuhiro Matsuo; Yasuhiro Yasutomi
Infection and immunity, 86, 11, 2018年11月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Suppressor of cytokine signaling 1 (SOCS1) is a negative regulator of JAK/STAT signaling and is induced by mycobacterial infection. To understand the major function of SOCS1 during infection, we established a novel system in which recombinant Mycobacterium bovis bacillus Calmette-Guérin expressed dominant-negative SOCS1 (rBCG-SOCS1DN) because it would not affect the function of SOCS1 in uninfected cells. When C57BL/6 mice and RAG1-/- mice were intratracheally inoculated with rBCG-SOCS1DN, the amount of rBCG-SOCS1DN in the lungs was significantly reduced compared to that in the lungs of mice inoculated with a vector control counterpart and wild-type BCG. However, these significant differences were not observed in NOS2-/- mice and RAG1-/- NOS2-/- double-knockout mice. These findings demonstrated that SOCS1 inhibits nitric oxide (NO) production to establish mycobacterial infection and that rBCG-SOCS1DN has the potential to be a powerful tool for studying the primary function of SOCS1 in mycobacterial infection. - C-Type Lectin Receptor DCAR Recognizes Mycobacterial Phosphatidyl-Inositol Mannosides to Promote a Th1 Response during Infection.
Kenji Toyonaga; Shota Torigoe; Yoshitomo Motomura; Takane Kamichi; Jennifer M Hayashi; Yasu S Morita; Naoto Noguchi; Yasushi Chuma; Hideyasu Kiyohara; Kazuhiro Matsuo; Hiroshi Tanaka; Yoshiko Nakagawa; Tetsushi Sakuma; Masaki Ohmuraya; Takashi Yamamoto; Masayuki Umemura; Goro Matsuzaki; Yasunobu Yoshikai; Ikuya Yano; Tomofumi Miyamoto; Sho Yamasaki
Immunity, 45, 6, 1245, 1257, 2016年12月20日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Phosphatidyl-inositol mannosides (PIM) are glycolipids unique to mycobacteria and other related bacteria that stimulate host immune responses and are implicated in mycobacteria pathogenicity. Here, we found that the FcRγ-coupled C-type lectin receptor DCAR (dendritic cell immunoactivating receptor; gene symbol Clec4b1) is a direct receptor for PIM. Mycobacteria activated reporter cells expressing DCAR, and delipidation of mycobacteria abolished this activity. Acylated PIMs purified from mycobacteria were identified as ligands for DCAR. DCAR was predominantly expressed in small peritoneal macrophages and monocyte-derived inflammatory cells in lungs and spleen. These cells produced monocyte chemoattractant protein-1 (MCP-1) upon PIM treatment, and absence of DCAR or FcRγ abrogated MCP-1 production. Upon mycobacterial infection, Clec4b1-deficient mice showed reduced numbers of monocyte-derived inflammatory cells at the infection site, impaired IFNγ production by T cells, and an increased bacterial load. Thus, DCAR is a critical receptor for PIM that functions to promote T cell responses against mycobacteria. - Simian immunodeficiency virus SIVmac239 infection and simian human immunodeficiency virus SHIV89.6P infection result in progression to AIDS in cynomolgus macaques of Asian origin
Tomotaka Okamura; Yusuke Tsujimura; Shogo Soma; Ichiro Takahashi; Kazuhiro Matsuo; Yasuhiro Yasutomi
JOURNAL OF GENERAL VIROLOGY, 97, 12, 3413, 3426, 2016年12月, [査読有り]
英語, 研究論文(学術雑誌) - MHCを視点とした免疫異常・感染症治療戦略の新展開 HIV-1ワクチン開発とその課題
志田 壽利; 加藤 誠一; 保富 康宏; 松尾 和浩; 三浦 智行; 五十嵐 樹彦; 張 険峰; 井上 誠; 成瀬 妙子; 木村 彰方
MHC: Major Histocompatibility Complex, 23, 2Suppl., 58, 58, (一社)日本組織適合性学会, 2016年10月
日本語 - Effects of Mycobacteria Major Secretion Protein, Ag85B, on Allergic Inflammation in the Lung
Yusuke Tsujimura; Hiroyasu Inada; Misao Yoneda; Tomoyuki Fujita; Kazuhiro Matsuo; Yasuhiro Yasutomi
PLOS ONE, 9, 9, e106807, 2014年09月, [査読有り]
英語, 研究論文(学術雑誌) - Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization
Kenta Watanabe; Akihiro Matsubara; Mitsuo Kawano; Satoru Mizuno; Tomotaka Okamura; Yusuke Tsujimura; Hiroyasu Inada; Tetsuya Nosaka; Kazuhiro Matsuo; Yasuhiro Yasutomi
VACCINE, 32, 15, 1727, 1735, 2014年03月, [査読有り]
英語, 研究論文(学術雑誌) - Immunogenicity and safety of the vaccinia virus LC16m8Δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol.
Sato H; Jing C; Isshiki M; Matsuo K; Kidokoro M; Takamura S; Zhang X; Ohashi T; Shida H
Vaccine, 31, 35, 3549, 3557, 2013年08月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), We compared the effect of the very strong pSFJ1-10 and moderately strong p7.5 promoters on the immunogenicity and pathogenicity of the replication-competent vaccinia virus (VV) LC16m8Δ (m8Δ) vector harboring the SIV gag gene in a vaccination regimen consisting of a recombinant BCG-SIVGag (rBCG-SIVGag) prime followed by a recombinant vaccinia boost. m8Δ/pSFJ/SIVGag synthesized more Gag protein than m8Δ/p7.5/SIVGag but replicated less efficiently in vitro. In addition, m8Δ/pSFJ/SIVGag was less pathogenic and elicited Gag-specific IFN-γ(+), CD107a(+), CD8(+) cells more efficiently than m8Δ/p7.5/SIVGag. Vaccination by this regimen elicited long-lasting Gag-specific CD8(+) T cells, the majority of which showed a CCR7(-) phenotype at over 8 weeks post-boost. Tetramer staining analyses revealed maintenance of Gag specific tetramer(+), CD62L(-), CD8(+) T cells for long time in vaccinated mice. However, Gag expression increased the neurotoxicity of the vaccinia vector, indicating the necessity of safety testing for each recombinant VV. We propose that this recombinant BCG prime-m8Δ/pSFJ/HIVGag boost regimen would be a promising vaccination procedure for preventing HIV infection. - Single systemic administration of Ag85B of mycobacteria DNA inhibits allergic airway inflammation in a mouse model of asthma.
Karamatsu K; Matsuo K; Inada H; Tsujimura Y; Shiogama Y; Matsubara A; Kawano M; Yasutomi Y
Journal of asthma and allergy, 5, 71, 79, 2012年, [査読有り] - Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control.
Matsuo K; Yasutomi Y
Tuberculosis research and treatment, 2011, 574591, 2011年, [査読有り] - Intradermal delivery of recombinant vaccinia virus vector DIs induces gut-mucosal immunity.
Yoshino N; Kanekiyo M; Hagiwara Y; Okamura T; Someya K; Matsuo K; Ami Y; Sato S; Yamamoto N; Honda M
Scandinavian journal of immunology, 72, 2, 98, 105, 2, 2010年08月, [査読有り] - The immune responses of the prime-boost regimen with rBCG-E12 and rDIs-E12 candidate vaccine
P. Leangaramgul; S. Sapsutthipas; K. Balachandra; K. Matsuo; T. Hamano; M. Honda
ANIMAL CELL TECHNOLOGY: BASIC & APPLIED ASPECTS, VOL 14, 255, +, 2006年, [査読有り]
英語, 研究論文(国際会議プロシーディングス) - Replication-defective HIV isolated from seronegative individuals at high risk for HIV infection.
Takaichi Hamano; Kazuhiro Matsuo; Yurina Hibi; Naoko Takahashi; Yoshio Mabuchi; Tsuyoshi Soji; Shinji Irie; Hideki Yanai; Takashi Hara; Shudo Yamazaki; Naoki Yamamoto; Hiroshi Takaku; Takashi Okamoto
Nucleic acids symposium series (2004), 49, 99, 100, 2005年, [国際誌]
英語, 研究論文(学術雑誌), We have identified a mutant human immunodeficiency virus type 1 (HIV-1) CRF01_AE that contains a single nucleotide mutation in gag gene from 4 HIV-1 seronegative drug users in Thailand. We found A to G mutation at the nucleotide position 75 of gag p17 gene (A75G) not changing the amino acid sequence. The mutant HIV-1 molecular clones were examined for their replication capability. Although the mutation dramatically reduced the level of virion production, it did not affect the amounts of viral protein synthesis within the transfected cells. In addition, this mutation did not affect the levels of Gag polyproteins. Furthermore, electron microscopic examinations have revealed a dramatic reduction of the virion production and perturbation of viral morphogenesis at the cytoplasmic membrane. These results indicate that the A75G mutation is attributable to the long-term sero-negativity of individuals at high risk of HIV-1 infection and suggest a novel mechanism that regulates HIV production. - Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys (Retracted Article. See vol 79, pg 3229, 2005)
Y Izumi; Y Ami; K Matsuo; K Someya; T Sata; N Yamamoto; M Honda
JOURNAL OF VIROLOGY, 77, 24, 13248, 13256, 2003年12月, [査読有り]
英語, 研究論文(学術雑誌) - III-2. Study on recombinant BCG
K. Matsuo; R. Yamaguchi; A. Yamazaki; K. Terasaka; S. Nagai; H. Tasaka; C. Abe; M. Totsuka; H. Yukitake; K. Kobayashi; N. Ohara; T. Yamada
Kekkaku, 66, 9, 615, 619, 1991年, [査読有り]
日本語, 研究論文(国際会議プロシーディングス)
- 抗酸菌症に対するワクチン開発の現状
松尾和浩, 結核, 99, 7, 209, 211, 2024年, [招待有り], [筆頭著者]
日本語, 記事・総説・解説・論説等(学術雑誌) - BCGの新たな可能性
水野 悟; 松尾和浩, 複十字, 418, 24, 25, 2024年, [招待有り]
日本語 - BCG-culture filtrate proteins(CFP)由来タンパク質Xによるアジュバント作用
渋谷 幸広; 水野 悟; 中馬 康志; 堀端 重男; 河野 央; 千木 あさみ; 横川 絵美; 晝川 祐希菜; 松尾 和浩, 臨床とウイルス, 51, 3, 111, 111, 2023年09月
日本臨床ウイルス学会, 日本語 - BCG-culture filtrate protein(CFP)によるアジュバント作用
水野 悟; 中馬 康志; 渋谷 幸広; 堀端 重男; 千木 あさみ; 横川 絵美; 晝川 祐希菜; 松尾 和浩, 臨床とウイルス, 51, 3, 188, 188, 2023年09月
日本臨床ウイルス学会, 日本語 - SIV-gag rBCGプライムワクシニアm8Δブーストにおけるワクシニアプロモーターの検討
佐藤洋隆; 陳晶; 張険峰; 松尾和浩; 志田壽利, 日本ウイルス学会学術集会プログラム・抄録集, 60th, 2012年 - Low Dose Immunization of Codon-Optimized Recombinant BCG Confers Long-Lasting SIV-Specific Memory T Cells After Recombinant Vaccinia Boost in Macaques
M. Kanekiyo; Y. Ami; K. Matsuo; K. Someya; N. Yamamoto; M. Honda, AIDS RESEARCH AND HUMAN RETROVIRUSES, 27, 10, A96, A96, 2011年10月
英語, 研究発表ペーパー・要旨(国際会議) - Paradigm change in immune correlation: cellular or humoral?
Kazuhiro Matsuo; Naoki Yamamoto, EXPERT REVIEW OF VACCINES, 9, 9, 985, 987, 2010年09月
英語, その他 - Different Vaccine Vectors Delivering the Same Antigen Elicit CD8(+) T Cell Responses with Distinct Clonotype and Epitope Specificity
Mitsuo Honda; Rui Wang; Wing-Pui Kong; Masaru Kanekiyo; Wataru Akahata; Ling Xu; Kazuhiro Matsuo; Kannan Natarajan; Howard Robinson; Tedi E. Asher; David A. Price; Daniel C. Douek; David H. Margulies; Gary J. Nabel, JOURNAL OF IMMUNOLOGY, 183, 4, 2425, 2434, 2009年08月
英語 - Immunogenicity of newly constructed attenuated vaccinia strain LC16m8Δ that expresses SIV Gag protein
Hajime Suzuki; Minoru Kidokoro; Ismael Ben Fofana; Takashi Ohashi; Tomotaka Okamura; Kazuhiro Matsuo; Naoki Yamamoto; Hisatoshi Shida, Vaccine, 27, 7, 966, 971, 2009年02月11日
英語 - Administration of Ag85B showed therapeutic effects to Th2-type cytokine-mediated acute phase atopic dermatitis by inducing regulatory T cells
Hitoshi Mori; Keiichi Yamanaka; Kazuhiro Matsuo; Ichiro Kurokawa; Yasuhiro Yasutomi; Hitoshi Mizutani, ARCHIVES OF DERMATOLOGICAL RESEARCH, 301, 2, 151, 157, 2009年02月
英語 - Mucosal administration of completely non-replicative vaccinia virus recombinant Dairen I strain elicits effective mucosal and systemic immunity
N. Yoshino; M. Kanekiyo; Y. Hagiwara; T. Okamura; K. Someya; K. Matsuo; Y. Ami; S. Sato; N. Yamamoto; M. Honda, SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 68, 5, 476, 483, 2008年11月
英語 - A single-nucleotide synonymous mutation in the gag gene controlling human immunodeficiency virus type 1 virion production
Takaichi Hamano; Kazuhiro Matsuo; Yurina Hibi; Ann Florence B. Victoriano; Naoko Takahashi; Yosio Mabuchi; Tsuyoshi Soji; Shinji Irie; Pathom Sawanpanyalert; Hideki Yanai; Takashi Hara; Shudo Yamazaki; Naoki Yamamoto; Takashi Okamoto, JOURNAL OF VIROLOGY, 81, 3, 1528, 1533, 2007年02月
英語 - Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity (vol 79, pg 12871, 2005)
Yasushi Ami; Yasuyuki Izumi; Kazuhiro Matsuo; Kenji Someya; Masaru Kanekiyo; Shigeo Horibata; Naoto Yoshino; Koji Sakai; Katsuaki Shinohara; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda, JOURNAL OF VIROLOGY, 80, 20, 10288, 10288, 2006年10月
英語, その他 - Intradermal and oral immunization with recombinant Mycobacterium bovis BCG expressing the simian immunodeficiency virus Gag protein induces long-lasting, antigen-specific immune responses in guinea pigs
M Kawahara; K Matsuo; M Honda, CLINICAL IMMUNOLOGY, 119, 1, 67, 78, 2006年04月
英語 - Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol
K Someya; Y Ami; T Nakasone; Y Izumi; K Matsuo; S Horibata; KQ Xin; H Yamamoto; K Okuda; N Yamamoto; M Honda, JOURNAL OF IMMUNOLOGY, 176, 3, 1784, 1795, 2006年02月
英語 - Recombinant vaccinia dls expressing simian immunodeficiency virus Gag and Pol in mammalian cells induces efficient cellular immunity as a safe immunodeficiency virus vaccine candidate
Tomotaka Okamura; Kenji Someya; Kazuhiro Matsuo; Atsuhiko Hasegawa; Naoki Yamamoto; Mitsuo Honda, MICROBIOLOGY AND IMMUNOLOGY, 50, 12, 989, 1000, 2006年
英語 - Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity
Y Ami; Y Izumi; K Matsuo; K Someya; M Kanekiyo; S Horibata; N Yoshino; K Sakai; K Shinohara; S Matsumoto; T Yamada; S Yamazaki; N Yamamoto; M Honda, JOURNAL OF VIROLOGY, 79, 20, 12871, 12879, 2005年10月
英語 - Ag85B of mycobacteria elicits effective CTL responses through activation of robust adjuvant in DNA vaccine
S Takamura; K Matsuo; Y Takebe; Y Yasutomi, JOURNAL OF IMMUNOLOGY, 175, 4, 2541, 2547, 2005年08月
英語 - Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobactetium bovis bacille Calmette-Guerin expressing human immunodeficiency virus type 1 Gag
M Kanekiyo; K Matsuo; M Hamatake; T Hamano; T Ohsu; S Matsumoto; T Yamada; S Yamazaki; A Hasegawa; N Yamamoto; M Honda, JOURNAL OF VIROLOGY, 79, 14, 8716, 8723, 2005年07月
英語 - Specific immune response and pathological findings in BALB/c mice inoculated with recombinant BCG expressing HIV-1 antigen
W Wiriyarat; S Sukpanichnant; N Sittisombut; K Ballachandra; D Promkhatkaew; R Butraporn; R Sutthent; J Boonlong; K Matsuo; M Honda; P Warachit; P Puthavathana, ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 23, 1, 41, 51, 2005年03月
英語 - Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys (Retraction of vol 77, pg 13248, 2003)
Y Izumi; Y Ami; K Matsuo; K Someya; T Sata; N Yamamoto; M Honda, JOURNAL OF VIROLOGY, 79, 5, 3229, 3229, 2005年03月
英語, その他 - Vaccination of rhesus macaques with recombinant Mycobactetium bovis bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif
K Someya; D Cecilia; Y Ami; T Nakasone; K Matsuo; S Burda; H Yamamoto; N Yoshino; M Kaizu; S Ando; K Okuda; S Zolla-Pazner; S Yamazaki; N Yamamoto; M Honda, JOURNAL OF VIROLOGY, 79, 3, 1452, 1462, 2005年02月
英語 - A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity
K Someya; KQ Xin; K Matsuo; K Okuda; N Yamamoto; M Honda, JOURNAL OF VIROLOGY, 78, 18, 9842, 9853, 2004年09月
英語 - Determination of HIV type ICRF01_AE gag p17 and env-V3 consensus sequences for HIV/AIDS vaccine design
T Hamano; P Sawanpanyalert; H Yanai; S Piyaworawong; T Hara; S Sapsutthipas; J Phromjai; S Yamazaki; N Yamamoto; P Warachit; M Honda; K Matsuo, AIDS RESEARCH AND HUMAN RETROVIRUSES, 20, 3, 337, 340, 2004年03月
英語 - Immunization with recombinant Calmette-Guerin bacillus (BCG)-hepatitis C virus (HCV) elicits HCV-specific cytotoxic T lymphocytes in mice
S Uno-Furuta; K Matsuo; S Tamaki; S Takamura; A Kamei; Kuromatsu, I; M Kaito; Y Matsuura; T Miyamura; Y Adachi; Y Yasutomi, VACCINE, 21, 23, 3149, 3156, 2003年07月
英語 - Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces enhanced immune responses against the inserted HIV-1V3 antigen
M Kawahara; K Matsuo; T Nakasone; T Hiroi; H Kiyono; S Matsumoto; T Yamada; N Yamamoto; M Honda, VACCINE, 21, 3-4, 158, 166, 2002年12月
英語 - Structural analysis of vaccinia virus dls strain: Application as a new replication-deficient viral vector
K Ishii; Y Ueda; K Matsuo; Y Matsuura; T Kitamura; K Kato; Y Izumi; K Someya; T Ohsu; M Honda; T Miyamura, VIROLOGY, 302, 2, 433, 444, 2002年10月
英語 - Characteristic of HIV-1 in V3 loop region based on seroreactivity and amino acid sequences in Thailand
K Balachandra; K Matsuo; R Sutthent; N Hoisanka; N Boonsarthorn; P Sawanpanyalert; P Warachit; S Yamazaki; M Honda, ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 20, 2, 93, 98, 2002年06月
英語 - Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development
S Yamamoto; T Yamamoto; Y Nojima; K Umemori; S Phalen; DN McMurray; E Kuramoto; S Iho; R Takauji; Y Sato; T Yamada; N Ohara; S Matsumoto; Y Goto; K Matsuo; T Tokunaga, JAPANESE JOURNAL OF INFECTIOUS DISEASES, 55, 2, 37, 44, 2002年04月
英語, 書評論文,書評,文献紹介等 - Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B’ strains by recombinant Mycobacterium bovis BCG-based candidate vaccine.
Chujoh Y; Matsuo K; Yoshizaki H; Nakasatomi T; Someya K; Okamoto Y; Naganawa S; Haga S; Yoshikura H; Yamazaki A; Yamazaki S; Honda M, Vaccine, 20, 5-6, 797, 804, 2001年12月
英語 - Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an alpha antigen from mycobacteria
Kuromatsu, I; K Matsuo; S Takamura; G Kim; Y Takebe; J Kawamura; Y Yasutomi, CANCER GENE THERAPY, 8, 7, 483, 490, 2001年07月
英語 - 抗酸菌抗原DNAワクチンとrBCGワクチンのモルモット免疫応答及び結核防御効果
山本 三郎; 野島 康弘; 梅森 清子; 野間口 博子; 大原 直也; 山田 毅; 山本 十糸子; 佐藤 由紀夫; 松本 壮吉; 松尾 和浩, 日本細菌学雑誌, 56, 1, 315, 315, 2001年02月
日本細菌学会, 日本語 - PROTECTIVE IMMUNE-RESPONSES INDUCED BY SECRETION OF A CHIMERIC SOLUBLE-PROTEIN FROM A RECOMBINANT MYCOBACTERIUM-BOVIS BACILLUS-CALMETTE-GUERIN VECTOR CANDIDATE VACCINE FOR HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN SMALL ANIMALS
M HONDA; K MATSUO; T NAKASONE; Y OKAMOTO; H YOSHIZAKI; K KITAMURA; W SUGIURA; K WATANABE; Y FUKUSHIMA; S HAGA; Y KATSURA; H TASAKA; K KOMURO; T YAMADA; T ASANO; A YAMAZAKI; S YAMAZAKI, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 92, 23, 10693, 10697, 1995年11月
英語 - SECRETION OF MPB64 ANTIGEN BY A RECOMBINANT CLONE OF MYCOBACTERIUM-SMEGMATIS - CHARACTERIZATION AND APPLICATION FOR THE DIAGNOSIS OF TUBERCULOSIS
H TASAKA; E SHIGETO; K MATSUO; R YAMAGUCHI; S HAGA; A YAMAZAKI; T YAMAZAKI; S NAGAI; RM NAKAMURA, SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 42, 4, 487, 492, 1995年10月
英語 - DELAYED-TYPE HYPERSENSITIVITY TO A RECOMBINANT MYCOBACTERIAL ANTIGEN, MPB64, IN GUINEA-PIGS SENSITIZED TO MYCOBACTERIUM-TUBERCULOSIS OR MYCOBACTERIUM-BOVIS BCG
S HAGA; R YAMAGUCHI; S NAGAI; K MATSUO; A YAMAZAKI; RM NAKAMURA, JOURNAL OF LEUKOCYTE BIOLOGY, 57, 2, 221, 225, 1995年02月
英語 - CYTOTOXIC T-LYMPHOCYTE RESPONSE IN MICE INDUCED BY A RECOMBINANT BCG VACCINATION WHICH PRODUCES AN EXTRACELLULAR ALPHA ANTIGEN THAT FUSED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE IMMUNODOMINANT DOMAIN IN THE V3 LOOP
M KAMEOKA; Y NISHINO; K MATSUO; N OHARA; T KIMURA; A YAMAZAKI; T YAMADA; K IKUTA, VACCINE, 12, 2, 153, 158, 1994年02月
英語 - CLONING AND SEQUENCING OF THE GENE FOR ALPHA-ANTIGEN FROM MYCOBACTERIUM-AVIUM AND MAPPING OF B-CELL EPITOPES
N OHARA; K MATSUO; R YAMAGUCHI; A YAMAZAKI; H TASAKA; T YAMADA, INFECTION AND IMMUNITY, 61, 4, 1173, 1179, 1993年04月
英語 - HIGHLY CONSERVED EPITOPE DOMAIN IN MAJOR CORE PROTEIN P24 IS STRUCTURALLY SIMILAR AMONG HUMAN, SIMIAN AND FELINE IMMUNODEFICIENCY VIRUSES
K MATSUO; Y NISHINO; T KIMURA; R YAMAGUCHI; A YAMAZAKI; T MIKAMI; K IKUTA, JOURNAL OF GENERAL VIROLOGY, 73, 2445, 2450, 1992年09月
英語 - CLONING AND EXPRESSION OF THE GENE FOR THE AVI-3 ANTIGEN OF MYCOBACTERIUM-AVIUM AND MAPPING OF ITS EPITOPES
R YAMAGUCHI; K MATSUO; A YAMAZAKI; M TAKAHASHI; Y FUKASAWA; M WADA; C ABE, INFECTION AND IMMUNITY, 60, 3, 1210, 1216, 1992年03月
英語 - FUSION PROTEIN BASED EPITOPE MAPPING OF THE MPB57 PROTEIN FROM MYCOBACTERIUM-BOVIS BCG AND ITS EPITOPE INSERTION INTO THE NATIVE PROTEIN
R YAMAGUCHI; K MATSUO; A YAMAZAKI; H KAGAWA; S NAGAI; T YAMADA, CANADIAN JOURNAL OF MICROBIOLOGY, 37, 1, 7, 13, 1991年01月
英語 - ESTABLISHMENT OF A FOREIGN ANTIGEN SECRETION SYSTEM IN MYCOBACTERIA
K MATSUO; R YAMAGUCHI; A YAMAZAKI; H TASAKA; K TERASAKA; M TOTSUKA; K KOBAYASHI; H YUKITAKE; T YAMADA, INFECTION AND IMMUNITY, 58, 12, 4049, 4054, 1990年12月
英語 - CLONING AND EXPRESSION OF THE GENE FOR THE CROSS-REACTIVE ALPHA-ANTIGEN OF MYCOBACTERIUM-KANSASII
K MATSUO; R YAMAGUCHI; A YAMAZAKI; H TASAKA; K TERASAKA; T YAMADA, INFECTION AND IMMUNITY, 58, 2, 550, 556, 1990年02月
英語 - COMPLETE NUCLEOTIDE-SEQUENCE OF IMMUNOGENIC PROTEIN-MPB70 FROM MYCOBACTERIUM-BOVIS BCG
K TERASAKA; R YAMAGUCHI; K MATSUO; A YAMAZAKI; S NAGAI; T YAMADA, FEMS MICROBIOLOGY LETTERS, 58, 2-3, 273, 276, 1989年04月
英語 - CLONING AND CHARACTERIZATION OF THE GENE FOR IMMUNOGENIC PROTEIN MPB64 OF MYCOBACTERIUM-BOVIS BCG
R YAMAGUCHI; K MATSUO; A YAMAZAKI; C ABE; S NAGAI; K TERASAKA; T YAMADA, INFECTION AND IMMUNITY, 57, 1, 283, 288, 1989年01月
英語 - IMMUNOGENIC PROTEIN-MPB57 FROM MYCOBACTERIUM-BOVIS BCG - MOLECULAR-CLONING, NUCLEOTIDE-SEQUENCE AND EXPRESSION
R YAMAGUCHI; K MATSUO; A YAMAZAKI; S NAGAI; K TERASAKA; T YAMADA, FEBS LETTERS, 240, 1-2, 115, 117, 1988年11月
英語 - CLONING AND EXPRESSION OF THE MYCOBACTERIUM-BOVIS BCG GENE FOR EXTRACELLULAR ALPHA-ANTIGEN
K MATSUO; R YAMAGUCHI; A YAMAZAKI; H TASAKA; T YAMADA, JOURNAL OF BACTERIOLOGY, 170, 9, 3847, 3854, 1988年09月
英語
■ 共同研究・競争的資金等の研究課題
- SIV感染サルモデルでのCTL増強型組換えBCG/ワクシニアエイズワクチンの評価
科学研究費助成事業
2018年04月01日 - 2021年03月31日
松尾 和浩; 志田 壽利; 三浦 智行
抗原の細胞内でのプロセシングが促進され免疫系に到達しやすくするために、PEST配列を組み込んだSIV抗原遺伝子を導入したBCGウレアーゼ欠損株(rBCG-SIVgag, SIVpol, SIVrtn, SIVenv)及び同様の抗原遺伝子を導入したワクシニアウイルスLC16m8Δ株をそれぞれ構築した。。
インド産アカゲザルにrBCG混合物を接種後、ワクシニア混合物で2回ブーストを行った所、3頭の内1頭で強いキラーT細胞の活性を確認した。SIVmac攻撃接種の結果、活性が強かった1頭でセットポイントのウイルス量を検出限界に近いレベルまで抑制し、キラーT細胞応答と感染防御能の相関が示唆された。
日本学術振興会, 基盤研究(C), 日本ビーシージー製造株式会社(日本BCG研究所), 18K06049 - ヒトパラインフルエンザ2型ウイルスを用いた粘膜免疫誘導型結核ワクチンの開発
科学研究費助成事業
2012年04月01日 - 2014年03月31日
渡邉 健太; 松尾 和浩
結核ワクチン抗原Ag85Bをヒトパラインフルエンザ2型ウイルスに組み込んだ新規結核ワクチン(hPIV2-Ag85B)の開発を行った。これを複数回、経鼻投与により免疫したマウスにおいて結核菌の攻撃接種を行ったところ、肺においては結核菌の菌数に顕著な減少が認められた。さらに、抗原特異的なIFN-γ産生細胞数の上昇も認められた。また、このウイルスベクター自体がアジュバント効果を持ち、呼吸器粘膜の活性化に作用し得ることも示唆された。以上の結果より、rhPIV2-Ag85Bは新しい結核ワクチンとして有用であると考えられる。
日本学術振興会, 若手研究(B), 独立行政法人医薬基盤研究所, 24790492 - SOCS1アンタゴニストを組み込んだBCGを用いた新規結核ワクチンの開発
科学研究費助成事業
2010年 - 2011年
渡邉 健太; 松尾 和浩
新規結核ワクチンとして、SOCS分子の変異体アンタゴニストを発現する組換えBCGを作製し、マウスを用いてそのワクチン効果を検討した。組換えBCGを免疫したマウスでは、結核抗原特異的な免疫応答が既存のBCGよりも強く認められ、また、攻撃接種実験においても高い防御効果が認められた。これらの結果より、この組換えBCGが新規結核ワクチンとして利用可能であることが示唆された。
日本学術振興会, 研究活動スタート支援, 独立行政法人医薬基盤研究所, 22890255 - 組換えBCGを利用した新規ワクチン開発
競争的資金
